Mobile Menu - OpenMobile Menu - Closed

Hearing on "The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight"

Date: 
Thursday, March 17, 2022 - 10:30am
Location: 
Hybrid Hearing in the John D. Dingell Room, 2123 of the Rayburn House Office Building, and Cisco Webex

The Subcommittee on Health of the Committee on Energy and Commerce held hybrid hearing that included both in-person and remote attendance on Thursday, March 17, 2022, at 10:30 a.m. This hearing took place in the John D. Dingell Room, 2123 of the Rayburn House Office Building, as well as remotely using Cisco Webex online video conferencing. The hearing is entitled, "The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight."

 

Key Documents

Memorandum from Chairman Pallone to the Subcommittee on Health

Opening Statement from Chairman Pallone as prepared for delivery

Opening Statement from Subcommittee Chairwoman Eshoo as prepared for delivery

 

Livestream

 

Legislation

H.R. 1730, the “Speeding Therapy Access Today Act of 2021”

H.R. 2565, the “FDA Modernization Act of 2021” 

H.R. 3085, the “Equity in Neuroscience and Alzheimer’s Clinical Trials Act of 2021” or the “ENACT Act of 2021”

H.R. 3927, the “Manufacturing API, Drugs, and Excipients in America Act” or the “MADE in America Act”

H.R. 4472, the “Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021” or the “BENEFIT Act of 2021”

H.R. 4511, the “FDA Advancing Collection of Transformative Science Act” or the “FACTS Act”

H.R. 5030, the “Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act” or the “DIVERSE Trials Act”

H.R. 5566, the “Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2021” or the “FORWARD Act of 2021”

H.R. 5585, the “Advanced Research Project Agency–Health Act” or the “ARPA-H Act”

H.R. 6000, the “Cures 2.0 Act”

H.R. 6584, the “Diverse and Equitable Participation in Clinical Trials Act” or the “DEPICT Act”

H.R. 6888, the “Helping Experts Accelerate Rare Treatments Act of 2022”

H.R. 6963, the “Accelerated Approval Integrity Act of 2022”

H.R. 6972, the “Give Kids a Chance Act”

H.R. 6973, the “Enhanced Access to Affordable Medicines Act”

H.R. 6988, the “Drug Manufacturing Innovation Act” 

H.R. 6996, the “Accelerating Access for Patients Act”

H.R. 7006, the “Improving the Nation’s Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act” or the “INSPECTIONS Act”

H.R. 7008, the “Pre-Approval Information Exchange Act” 

H.R. 7032, the “Increasing Transparency in Generic Drug Applications Act”

H.R. 7035, the “Biologics Market Transparency Act"

H.R. 7047, a bill to amend title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes

 

Witnesses

Jeff Allen, Ph.D.
President and CEO
Friends of Cancer Research

Testimony

 

Cartier Esham, Ph.D.
Chief Scientific Officer
Executive Vice President, Emerging Companies
Biotechnology Innovation Organization

Testimony

 

David Gaugh
Senior Vice President, Sciences and Regulatory Affairs
Association for Accessible Medicines

Testimony

 

Ruben Mesa, M.D.
Executive Director, Mays Cancer Center
UT Health San Antonio MD Anderson

Testimony

 

Reshma Ramachandran, M.D.
Chair, Doctors for America FDA Task Force
Physician-Fellow, Yale National Clinician Scholars Program
Yale School of Medicine

Testimony

 

Lucy Vereshchagina, Ph.D.
Vice President, Science and Regulatory Advocacy
Pharmaceutical Research and Manufacturers of America

Testimony

 

Issues: